Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

VOR Biopharma's valuation surged with telitacicept, yet dilution risks and share structure uncertainty maintain volatility.

Key Points GAAP earnings per share of $0.04 exceeded the consensus estimate of negative $0.08 for Q2 2025 No commercial revenue reported; company remains in pre-revenue phase with product launches ...

With concerns over a lack of healthcare housing in the Brass City, a new project plans to add dozens of units to a vacant, ...

President Trump has ordered a “comprehensive internal review” of exhibitions and materials at several Smithsonian museums to ...

BIO-key International, Inc. Q2 2025 Earnings Conference August 13, 2025 10:00 AM ETCompany ParticipantsCecilia C.

All the latest Tottenham Hotspur news as Thomas Frank gears up for the new Premier League season with a defeat to PSG in the UEFA Super Cup ...